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Abstract: The association between the Pro12Ala polymorphism of the PPARγ2 gene, type 2 diabetes
(T2D), and obesity in certain ethnic populations has been reported. However, this relationship has not
yet been described among diabetes patients in Nigeria. This study investigated the relationship between
the Pro12Ala polymorphism in the PPARγ2 gene, obesity, and lipid abnormalities characterizing T2D
among patients in Nigeria. This case-control study recruited 73 T2D and 75 non-diabetic (ND) patients.
Demographic and clinical data were collected and blood glucose levels together with serum lipid profile
for patients were measured. Pro12Ala polymorphism in the PPARγ2 gene was genotyped by restriction
fragment length-Polymerase Chain Reaction (RFLP-PCR). The PPAR-γ2 gene (amplicon size = 270 base
pair) was successfully amplified for all samples. Following restriction enzyme digestion and analysis
by agarose gel electrophoresis, amplicons from samples showed a band of size 270 bp and were of
the wild homozygous Pro/Pro genotype. Ala12 variant was totally absent from the study population.
Obesity, estimated using Body Mass Index (BMI) and waist circumference (WC), was significantly
higher (p < 0.05) in T2D patients compared to the non-diabetic patients. More so, the prevalence of lipid
abnormalities; hypercholesterolaemia (TC > 200 mg/dL), hypertriglyceridaemia (TG > 150 mg/dL), high
HDL (>100 mg/dL), and low HDL (<50 mg/dL) was significantly greater (p < 0.001) in T2D patients
compared to non-diabetic patients. Results obtained further indicated lack of significant association
between PPAR-γ2 gene polymorphism, T2D, and obesity. However, obesity and dyslipidaemia were
strongly associated in T2D patients.
Keywords: type 2 diabetes; PPAR-γ2 gene; Pro12Ala polymorphism; obesity; lipid profile indices;
Nigeria; genetic association
1. Introduction
Diabetes is a major threat to humans affecting over 400 million people across the globe [1]. Among
the diabetic cases, the majority are due to type 2 diabetes (T2D) [1]. Several factors predispose people to
T2D, among which obesity constitutes a major risk factor and is highly associated with the disease [2].
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According to a WHO global report, over 650 million people were obese in 2016 [3]. On the other
hand, obesity is usually associated with dyslipidaemia, a major lipid abnormality characterised by
increased levels of total cholesterol (TC), triglyceride (TG), low density lipoprotein (LDL), and reduced
level of high density lipoprotein (HDL). Dyslipidaemia is highly prevalent and associated with T2D.
Hypertriglyceridaemia, a component of dyslipidaemia, is known to be the principal lipid abnormality
that promotes insulin resistance [4]. Hypertriglyceridaemia is responsible for increased production
and decreased clearance of lipoproteins leading to increased levels of free fatty acids (FFA) in the blood
stream [5,6].
In a healthy and non-diabetic state, insulin promotes triglyceride storage in adipocytes and prevents
lipolysis and release of FFAs. Peroxisome proliferator activated receptor protein (PPAR) is one of the
molecules which regulate triglyceride storage in adipocytes. PPAR is a nuclear receptor ligand-activated
transcription factor commonly expressed in adipose tissue, liver, and heart [7]. The gene exists in three
isoforms namely; PPAR-α, PPARβ/δ, and PPAR-γ. PPAR-γ has been shown to be the isoform that is
functionally related to diabetes [8] as it plays a major role in glucose metabolism, differentiation of
adipocytes, regulation of lipid metabolism, promotion of insulin sensitivity, and has beneficial effects
on plasma lipids [9,10]. Synthetic ligands of PPAR-γ such as rosiglitazone and pioglitazone have been
reported to facilitate increased serum HDL and reduced plasma triglyceride levels [11].
Several polymorphisms have been identified in the PPAR-γ2 gene [12]. The most important
is the Pro12Ala polymorphism on exon B of the PPAR-γ2 gene. This polymorphism is defined by
a CCA to GCA mutation on codon 12 changing a proline (Pro) to an alanine (Ala) [13]. Previous
studies have shown the Ala allele to confer reduced risk of diabetes development among ethnic groups,
such as Japanese-Americans [14,15]. The frequency of Ala allele among Asians and Africans is low
(1–3%) with most individuals having the Pro12 allele [16]. Though an expanding body of evidence
reports the relationship between the Pro12Ala polymorphism of the PPARγ2 gene and T2D and/or
obesity in some African populations [17–19], none of these studies assessed the polymorphism within
a Nigerian population.
2. Materials and Methods
2.1. Study Population and Design
This study was part of an ongoing case-control study involving T2D and non-diabetic (ND)
patients at Enugu State University Teaching Hospital (ESUTH) in Enugu, Nigeria. Ethical approval
was obtained from the ethical committee at ESUTH and the study was conducted in accordance with
the Helsinki Declaration. Written informed consent was obtained from all patients before recruitment
into the study. Patients above 30 years of age, who have not eaten for the past 12 h (overnight
fasting), without any critical or emergency health conditions or complications and not admitted at the
hospital were recruited for the study. Breastfeeding and/or pregnant women as well as HIV positive
patients were excluded from the study. T2D patients were those with at least a one-year history of the
disease, diagnosed according to the International Diabetic Federation (IDF) criteria [20]. ND patients,
who served as the control, were those without hyperglycaemia or diabetes.
2.2. Data Collection and Laboratory Analysis
Demographic information of patients including age and sex was obtained while the systolic blood
pressure (SBP) and diastolic blood pressure (DBP) were measured using an automatic sphygmomanometer.
Height, weight, and waist circumference (WC) of the patients were measured and the Body Mass index
(BMI) calculated. WC and BMI were used to classify obesity according to WHO standard. After interview,
2 mL of blood was collected from each patient, transferred into EDTA free tubes and the fasting blood sugar
(FBS) was measured using an Accucheck glucometer (Roche Diabetes Care, Inc., Burgess Hill, UK) according
to the glucose oxidase enzymatic method by Trinder [21]. Blood samples were then centrifuge at 5000 rpm
for 10 min and serum was obtained for the determination of TC, TG, LDL, and HDL using diagnostic kits
J. Clin. Med. 2018, 7, 69 3 of 7
from Randox Laboratories Ltd. (Co Antrim, UK) following the manufacturer’s recommended procedure.
TC was determined according to the enzymatic method of Allain et al. [22], TG was assayed as described
by Esders and Michira [23] and HDL was quantified by the precipitation method of Grove [24]. LDL was
calculated using the Freidwald’s [25] formula: LDL = TC− (TG/5)−HDL.
2.3. Genotyping of PPARγ2 Pro12Ala Variant
DNA was extracted using GeneJET Genomic DNA Purification kit (K0721, Thermo Fisher
Scientific Inc., Waltham, MA, USA). Extracted DNA samples were amplified by PCR and
analyzed for Pro12Ala polymorphism of the PPARγ2 gene by restriction fragment length
polymorphism-PCR (RFLP-PCR). The PCR amplification was carried out using the forward
(5′-GCCAATTCAAGCCCAGTC-3′) and the reverse (5′-GATATGTTTGCAGACAGTGTATC-3′)
primers. The PCR reaction mixture contained 12 µL of OneTaq Quick-Load 2X Master Mix with
standard buffer (New England Biolabs, Ipswich, MA, USA), 4 µL of each primer (40 uM), and 8 µL
of DNA sample (<10 ng) making a total volume of 28 µL. The reaction was carried out under the
following conditions: Initial denaturation at 95 ◦C for 15 min, followed by 34 cycles of denaturation at
95 ◦C for 1 min, annealing at 56 ◦C for 1 min and elongation at 72 ◦C for 1 min, with a final extension
at 72 ◦C for 10 min. The PCR product was visualised in a UV transilluminator (Bio Olympics, Ltd.,
Thousand Oaks, CA, USA) after electrophoresis on a 2% agarose gel to confirm the presence of the
PPARγ2 gene. Positive PCR products were digested overnight with Bst UI restriction enzyme at 37 ◦C.
The reaction mixture was set to a final volume of 20 µL containing 10 µL of amplicon, 0.4 µL of the Bst
UI (NEB), 2 µL of 10× smartcut buffer (NEB) and 8 µL of sterile water. The digested products were
separated by electrophoresis on a 3% agarose gel.
2.4. Statistical Analysis
Data were analyzed using Statistical Package for Social Science (SPSS version 16; IBM Analytics,
Armonk, NY, USA.). Results were expressed as mean ± Standard Error of Mean (S.E.M). Parametric
independent sample t-test was used to compare mean differences of the demographic and clinical
characteristics such as obesity (BMI and WC) and lipid profile indices (TC, TG, HDL, and LDL) between
T2D patients and ND patients. A p-value less than 0.05 was considered statistically significant.
3. Results
3.1. Baseline Characteristic of Participants
One hundred and forty-eight (148) subjects participated in the study. Among these subjects,
73 (49.3%) were T2D patients while 75 (50.7%) were ND patients (control). The demographic and clinical
characteristics of the patients are summarized in Table 1. FBS as well as the weight were significantly
higher (p < 0.05) in T2D patients compared with their non-diabetic counterparts while the height, DBP
and SBP did not show any significant differences between T2D patients and non-diabetic controls.
Table 1. Baseline and clinical characteristics of participants.
Characteristics T2D Patients ND Patients p-Value
Age (years) 56.83 ± 1.21 49.03 ± 1.89 0.001
Height (m) 1.58 ± 0.01 1.61 ± 0.01 0.179
Weight (kg) 78.85 ± 3.42 71.52 ± 1.95 0.043
SBP (mmHg) 132.69 ± 2.65 132.86 ± 3.23 0.967
DSP (mmHg) 78.80 ± 1.36 81.76 ± 2.24 0.240
FBS (mg/dL) 166.71 ± 11.39 65.75 ± 3.79 0.000
Values are presented as Mean ± S.E.M. Age, weight and FBS are significantly higher (p < 0.05) in T2D patients.
SBP = Systolic blood pressure; DSP = Diastolic blood pressure; FBS = Fasting blood sugar.
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3.2. Obesity and Lipid Profile Indices of Patients
BMI and WC were significantly higher (p < 0.05) in T2D patients compared to the control (Table 2).
Similarly, TC, TG, and LDL levels were significantly higher (p < 0.05) in T2D patients. HDL level was
significantly lower (p < 0.05) in T2D patients compared to non-diabetic participants. The prevalence
of obesity (based on BMI and WC) was significantly higher (p < 0.05) in T2D patients compared to
non-diabetic control participants. Moreover, the prevalence of lipid abnormalities (dyslipidaemia)
characterized by hypercholesterolaemia (TC > 200 mg/dL), hypertriglyceridaemia (TG > 150 mg/dL),
high HDL (>100 mg/dL), and low HDL (<50 mg/dL) was significantly greater (p < 0.001) in T2D
patients compared to non-diabetic patients.
Table 2. Comparison of obesity and lipid abnormalities in patients.
Parameter T2D Patients n (%) ND Patients n (%) p-Value
BMI (Kg/m2) 31.38 ± 1.41 31 (21.1) 27.81 ± 0.76 22 (15.0) 0.026
WC (cm) 100.15 ± 1.70 53 (36.1) 89.37 ± 2.25 32 (21.8) <0.001
TC (mg/dL) 291.78 ± 28.90 58 (39.4) 159.43 ± 7.77 11 (7.5) <0.001
TG (mg/dL) 241.33 ± 15.443 60 (40.8) 148.82 ± 7.59 31 (21.1) <0.001
LDL (mg/dL) 212.40 ± 29.42 41 (27.8) 78.96 ± 7.96 9 (6.2) <0.001
HDL (mg/dL) 33.55 ± 2.14 45 (30.6%) 62.74 ± 5.16 25 (17.0%) <0.001
Values are presented as Mean ± S.E.M. n = the number of patients and prevalence (%) of obesity based on BMI
and WC or number of patients with lipid abnormalities based on TC, TG, LDL, and HDL. BMI = Body mass index;
WC = Waist circumference; TC = total cholesterol; TG = triglyceride; LDL = Low density lipoprotein; HDL = High
density lipoprotein.
3.3. Genotyping for PPARγ2 Pro12Ala Polymorphism
The expected DNA fragment of the PPARγ2 gene after PCR amplification was 270 bp. After
a restriction digest, an electrophoretic band of 270 bp was observed for all samples indicating the
presence of the homozygous wild-type Pro/Pro genotype which lacks a restriction site (Figure 1)
while the mutant homozygous Ala/Ala genotype which has a restriction site was absent as no sample
showed band sizes of 227 and 43 bp. Also, the heterozygote Pro/Ala genotype was absent in the study
population. As such, the Ala12 variant was totally absent from the study population.
Figure 1. RFLP-PCR of PPARγ2 Pro12Ala Polymorphism. Samples were analyzed on a 3% agarose
gel after restriction digest. D01–D03 = Samples for diabetic patients; ND01–ND03 = Samples for
non-diabetic patients; UD = Undigested sample (control); MWM = Molecular weight marker.
4. Discussion
T2D which constitutes about 90% to 95% of all diabetic cases is increasingly on the rise in
Africa [26]. This disease has become a major public health problem of concern in Nigeria as recent
data has shown Nigeria to have the highest disease burden in the continent of Africa. Incidence
of obesity, one of the major risk factors of T2D, and diabetic dyslipidaemia are also on the increase
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in Nigeria [3]. The important role of PPARγ2 in the regulation of lipid metabolism coupled with
the reported association between PPARγ polymorphisms and T2D [15,27,28] further necessitate the
investigation of changes in the PPARγ2 gene among diabetic patients in Nigeria. The Ala variant
of the PPARγ gene is known to improve insulin sensitivity by altering transcriptional activities
and expression of PPAR-γ in adipocytes, thereby suppressing lipolysis and release of FFAs while
enhancing insulin’s action [29,30]. Though the Pro12Ala variant has shown to be associated with
T2D and obesity in various populations across the globe [17], such findings are yet to be revealed
in Nigeria. Thus, the Pro12Ala polymorphism and its association with T2D was investigated in this
study. Our finding revealed the presence of the homozygous Pro/Pro genotype in all participants;
both diabetic and non-diabetic patients, and complete absence of the homozygous Ala/Ala and
heterozygous Pro/Ala genotypes. As such, the Pro12 allele was 100% present while the Ala12 allele
was totally absent in the population. This finding concurs with previous findings in Cameroon which
also showed a complete absence of the Ala12 allele [20] and in Ghana with only one participant having
the Ala12 allele in more than a thousand participants (<0.001%) [31]. This confirms the findings of
previous studies which have shown Pro12Ala polymorphism to have a very low frequency (<3%)
in populations of African ancestry (African-Americans) [15,16] as well as in typical black Africans
population in South Africa and Ethiopian Africans [17]. Cameroon, Ghana, and Nigeria, which present
similar genetic profiles, all belong to the Sub-Saharan region of Africa suggesting that areas with
similar ethnicity selects particular genetic trait. As such, the prevalence of the Ala12 allele may vary
widely across various ethnic populations. The Caucasian population has been shown to have the
highest frequency of this polymorphism with almost 25%, followed by Native Americans with about
10%. Other ethnic populations such as the Japanese, South American, Indian, and Chinese present
a frequency less than 4% [14,15]. Findings from this present study may therefore suggest that the
Pro allele may be the wild type which originated from the African descendants particularly from
Sub-Saharan Africa and the Ala allele as the mutant type which may have emerged through evolution
and environmental changes as the native Africans migrated to other parts of the world.
A recent meta-analysis study showed the PPAR-γ2 Pro12Ala polymorphism to be associated
with obesity risk, suggesting that the Ala allele could increase obesity susceptibility particularly in
Caucasian and Asian populations [32]. Thus, it was also of interest to investigate the influence of the
Pro12Ala polymorphism on obesity and lipid abnormalities in T2D subjects. Though obesity indices
(BMI and WC) were significantly higher (p < 0.05) in T2D patients compared to the control and also,
dyslipidaemia characterised by elevated TC, TG, and LDL levels and reduced HDL was significantly
present (p < 0.05) in T2D patients, the complete absence of the Ala12 allele in the population limited
the assessment of the influence of this polymorphic variant on obesity and lipid abnormalities among
T2D subjects.
5. Conclusions
The Ala mutant allele of PPAR-γ2 was absent in this study and thus the Pro12Ala PPAR-γ2
polymorphism may not be associated with obesity and/or T2D in this population. However, obesity
and dyslipidaemia were associated with T2D. Our finding confirms previous findings around the
sub-Sahara region and other African ethnic group which have shown Ala12 allele to be totally absent
or have a very low frequency in African populations.
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